Media headlines about Threshold Pharmaceuticals (NASDAQ:MTEM) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Threshold Pharmaceuticals earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.4048948458727 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Threshold Pharmaceuticals (NASDAQ MTEM) traded up $0.34 during mid-day trading on Wednesday, reaching $8.30. 85,314 shares of the company traded hands, compared to its average volume of 95,098. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. Threshold Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $11.88.
A number of analysts recently weighed in on MTEM shares. ValuEngine lowered shares of Threshold Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research lowered shares of Threshold Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. Stifel Nicolaus reaffirmed a “hold” rating and set a $0.40 target price on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. Finally, Ladenburg Thalmann Financial Services assumed coverage on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. They set a “buy” rating and a $10.00 target price on the stock.
TRADEMARK VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/22/threshold-pharmaceuticals-mtem-earning-somewhat-favorable-media-coverage-accern-reports.html.
Threshold Pharmaceuticals Company Profile
Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.